[Current Data] Rule running report - 2024-06-29 10:48:13.940738

Nr2MedPage Today) -- MILAN -- The weight loss and diabetes drug tirzepatide resolved metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, according to the results of the SYNERGY-NASH phase II study.… succesfully run! 0 Anläufe!